The burden of rheumatoid arthritis and access to treatment: Outcome and cost-utility of treatments

European Journal of Health Economics

Volumn 8, Issue SUPPL. 8, 2008, Pages

  Kobelt, G ^a   Jonsson B ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Cost effectiveness; Modeling; Rheumatoid arthritis

Indexed keywords

ARTICLE; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH SERVICE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; WORK CAPACITY;

ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DISABLED PERSONS; EMPLOYMENT; HEALTH SERVICES ACCESSIBILITY; HUMANS; MODELS, ECONOMIC; REGISTRIES; TREATMENT OUTCOME;

EID: 38449084666     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-007-0091-0     Document Type: Article

References (60)

1. Scott, D., Pugner, K., Kaarela, K., et al.: The links between joint damage and disability in rheumatoid arthritis. Rheumatology 39, 122-132 (2000)
2. Pincus, T., Sokka, T., Wolfe, F.: Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum. 44, 1234-1236 (2001)
3. Riise, T., Jacobsen, B., Gran, J., et al.: Total mortalilty is increased in rheumatoid arthritis. A 17 year prospective study. Clin. Rheumatol. 20, 123-127 (2001)
4. Yelin, E., Turpin, L., Wong, B., Rush, S.: The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J. Rheumatol. 29, 1851-1857 (2002)
5. Chehata, J., Hassell, A., Clarke, S., et al.: Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology 40, 447-452 (2001)
6. Jönsson B.: Quality of life and health economics. Where is the link? Scand. J. Gastroenterol. 31(Suppl 221), 33-36 (1996)
7. Choi, H.K., Seeger, J.D., Kuntz, K.M.: A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J. Rheumatol. 29, 1156-1165 (2002)
8. Maetzel, A., Tugwell, P., Boers, M., group obotOER.: Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a reference case. J. Rheumatol. 30, 891-896 (2003)
9. Ware, J., Sherbourne, C., McHorney, C.: The MOS 36-Item Short Form Health Survey. Med. Care 31, 247-263 (1993)
10. DeJong, Z., van der Heijde, D., McKenna, S., Whalley, D.: The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br. J. Rheumatol. 36, 878-883 (1997)
11. Torrance, G.: Measurement of health state utilities for economic appraisal. A review. J. Health Econ. 5, 1-30 (1986)
12. Drummond, M., O'Brien, B., Stoddart, G., Torrance, G.: Methods for the economic evaluation of health care. Kluwer, Boston (1997)
13. Kobelt, G.: Health economics: introduction to economic evaluation. Office of Health Economics, London (1996)
14. EuroQol: Group EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16, 199-208 (1990)
15. Dolan, P., Gudex, C., Kind, P., Williams, A.: A social tariff for EuroQol: results from a UK general population survey. Centre for Health Economics, University of York, York. Report No.: Discussion paper 138 (1995)
16. Torrance, G.: Measurement of health state utilities for economic appraisal. A review. J. Health Econ. 5, 1-30 (1986)
17. Brazier, J., Roberts, J., Deverill, M.: The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21, 271-292 (2002)
18. Wolfe, F., Mitchell, D., Sibley, J. et al.: The mortality of rheumatoid arthritis. Arthritis Rheum. 37, 481-494 (1994)
19. Symmons, D., Jones, M., Scott, D., Prior P.: Long-term mortality outcome in patients with rheumatoid arthrits: early presenters continue to do well. J. Rheumatol. 25, 1072-1077 (1998)
20. Wallberg-Jonsson, S., Ohlman, M., Dahlqvist S.: Cardiovascular morbidity and mortality in patients with seroposivie rheumatoid arthritis in Northern Sweden. J. Rheumatol. 24, 445-451 (1997)
21. Jacobsson, L.T., Turesson, C., Gulfe, A., et al.: Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32, 1213-1218 (2005)
22. Jacobsson, L.T., Turesson, C., Nilsson, J.A., et al.: Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 670-675 (2007)
23. Kobelt, G.: Health economic issues in rheumatoid arthritis. Scand. J. Rheumatol. 35, 415-425 (2006)
24. Kobelt, G., Eberhardt, K., Jönsson, L., Jönsson, B.: Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 42, 347-356 (1999)
25. Kobelt, G., Jönsson, L., Lindgren, P., et al.: Modelling the Progression of rheumatoid arthritis. A two-country model to estimate costs and consequences of RA. Arthritis Rheum. 46, 2310-2319 (2002)
26. Guillemin, F., Briancon, S., Pourel, J.: Functional disability in rheumatoid arthritis: two different models in early and established disease. J. Rheumatol. 26, 800-804 (1992)
27. Aletaha, D., Smolen, J., Ward, M.M.: Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum. 54, 2784-2792 (2006)
28. Fries, J., Spitz, P., Kraines, R., Holman, H.: Measurement of patient outcome in arthritis. Arthritis Rheum. 23, 137-145 (1980)
29. Kobelt, G., Lindgren, P., Lindroth, Y., et al.: Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 44, 1169-1175 (2005)
30. Hulsemann, J.L., Ruof, J., Zeidler, H., Mittendorf, T.: Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'. Rheumatol. Int. 26, 704-711 (2005)
31. Lajas, C., Abasolo, L., Bellajdel, B., et al.: Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 49, 64-70 (2003)
32. Kobelt, G., Richard, B., Peeters, P., Sany, J.: Costs and quality of life of patients with RA in France. ACR abstract, Bone, Joint, Spine (in press) (2006)
33. Marra, C.A., Woolcott, J.C., Kopec, J.A., et al.: A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc. Sci. Med. 60, 1571-1582 (2005)
34. Marra C.A., Marion S.A., Guh D.P., et al.: Not all "quality-adjusted life years" are equal. J. Clin. Epidemiol. 60, 616-624 (2007)
35. Thompson, M., Leighton-Read, J., Hutchings, C., et al.: The cost effectiveness of auranofin. Results of a randomized clinical trial. J. Rheumatol. 15, 35-42 (1988)
36. Drummond, M.F., Barbieri, M., Wong, J.B.: Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference? Med. Decis. Making 25, 520-533 (2005)
37. Bansback, N.J., Regier, D.A., Ara, R., et al.: An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 65, 473-496 (2005)
38. Smolen, K., Kalden, J., Scott, D., et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized multicentre trial. Lancet 353, 259-266 (1999)
39. Emery, P., Breedveld, F., Lemmel, E., et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39, 655-665 (2000)
40. Strand, V., Tugwell, P., Bombardier, C., et al.: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum. 42, 1870-1878 (1999)
41. Kobelt, G., Lindgren, P., Young, A., Eberhardt, K.: Cost and effects of leflunomide in the UK. Eur. J. Health Econ. 3, 173-179 (2002)
42. Maini, R., Group tAS.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354, 1932-1939 (1999)
43. Kobelt, G., Jönsson, L., Young, A., Eberhardt, K.: The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 42, 326-335 (2003)
44. Weinblatt, M., Kremer, J., Bankhurst, A., et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253-312 (1999)
45. Jobanputra, P., Barton, P., Bryan, S., et al.: The clinical effectiveness and cost-effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab. University of Birmingham, Birmingham (2004)
46. Barton, P., Jobanputra, P., Wilson, J., et al.: The use of modelling to evaluate new drugs for patients with chronic conditions: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol. Assess. 8, 1-91 (2004)
47. Kobelt, G., Eberhardt, K., Geborek, P.: TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann. Rheum. Dis. 63, 4-10 (2004)
48. Wong, J., Singh, G., Kavanough, A.: Estimating the cost-effectiveness of infliximab for rheumatoid arthritis. Am. J. Med. 113, 400-408 (2002)
49. Moreland, L., Schiff, M., Baumgartner, S., et al.: Etanercept therapy in rheumatoid arthritis. Ann. Intern. Med. 130, 478-486 (1999)
50. Brennan, A., Bansback, N., Nixon, R., et al.: Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) (2007)
51. Bansback, N.J., Brennan, A., Ghatnekar, O.: Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann. Rheum. Dis. 64, 995-1002 (2005)
52. Klareskog, L., van der Heijde, D., de Jager, J.P., et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675-681 (2004)
53. Kobelt, G., Lindgren, P., Singh, A., Klareskog, L.: Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann. Rheum. Dis. 64, 1174-1179 (2005)
54. Wolfe, F., Michaud, K., Pincus, T.: Do rheumatology cost-effectiveness analyses make sense?. Rheumatology 43, 4-6 (2004)
55. Brennan, A., Bansback, N., Reynolds, A., Conway, P.: Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 43, 62-72 (2004)
56. Zink, A., Strangfeld, A., Schneider, M., et al.: Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 54, 3399-3407 (2006)
57. Wong, J., Ramey, D., Singh, G.: Long-term morbidity, mortality and economics of rheumatoid arthritis. Arthritis Rheum. 44, 2746-2749 (2001)
58. Kobelt, G., Jönsson, L., Lindqvist, E., Eberhardt, K.: Cost-effectiveness of infliximab in Sweden. ACR San Francisco. Arthritis Rheum. (Abstract 2282) (2001)
59. Barbieri, M., Wong, J.B., Drummond, M.: The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics 23, 607-618 (2005)
60. Smolen, J., Breedveld, T., Burmester, G., et al.: Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann. Rheum. Dis. 59, 504-505 (2000)